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ABSTRACT 
 
Background: Cisplatin-based combination chemotherapy is standard treatment for metastatic 
urothelial carcinoma; however, the vast majority of patients experience disease progression. 
As systemic therapy alone is rarely curative for the treatment of metastatic urothelial cancer, 
not only are new therapies needed but also refinement of general treatment principles. Herein, 
we conducted a systematic review and meta-analysis to explore the role of metastasectomy in 
metastatic urothelial carcinoma.  
Methods: We conducted a systematic review of the literature regarding local treatment for 
metastatic urothelial carcinoma. An online electronic search of the PubMed/MEDLINE and 
EMBASE databases was performed to identify peer-reviewed articles. All procedures were 
performed according to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines. Information was then extracted including number of 
patients, gender, the site of the primary urothelial tumor, site of metastasis, chemotherapy 
before or after metastasectomy, overall survival (OS), and disease specific survival (DSS) 
after metastasectomy. A meta-analysis was performed with those studies with sufficient 
survival data to obtain pooled overall survival. The article quality was assessed using the 
Cochrane Handbook "risk of bias" tool.  
Results: Seventeen out of 3963 articles were eligible for review between 1990-2015, 
including a total of 412 patients. The mean time to recurrence after metastasectomy was 
14.25 months. The overall survival from time of metastasectomy ranged from 2 to 60 months. 
Pooled analyses of studies reported survival data revealed an improved overall survival for 
patients treated with metastasectomy compared with non-surgical treatment of metastatic 
lesions (HR 0.63; 95% CI, 0.49-0.81). All, except for three studies, were retrospective and 
non-randomized, leading to a high risk of bias associated with patient selection, patient 
attrition, and reporting. Such high potential of selection bias may lead to higher OS than 
expected. Additionally, treatment and outcome details reported across studies was highly 
variable.  
Conclusions: Limited conclusions can be drawn from the available literature exploring the 
role of metastasectomy in the management of metastatic urothelial cancer due to lack of 
uniform reporting elements and multiple sources of bias particularly related to a lack of 
prospective randomized trials. As a subset of patients treated with metastasectomy achieve 
durable disease control, this approach may be considered for select patients. 
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